Clinical trial
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube…
NCT00317772 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00317772 |
|---|---|
| Title | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer |
| Official title | A Phase I/II Study of Weekly Topotecan and Gefitinib (Iressa) in Patients With Platinum-Resistant Ovarian, Peritoneal, of Fallopian Tube Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | AstraZeneca Industry GlaxoSmithKline |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer |
| Intervention type | Drug |
| Interventions | Topotecan, Gefitinib |
| Enrollment | 19 |
| Start date | Sep 2, 2004 |
| Primary completion | Nov 4, 2020 |
| Completion | Nov 4, 2020 |
| First posted | Apr 25, 2006 |
| Last update posted | Feb 7, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: